<p>Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain</p>

Abstract

Purpose Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. Methods A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making. Results The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). Conclusion The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.

Adherence to disease modifying therapies in patients with multiple sclerosis

“…Daþ niau sia ne draus min go var to ji mo prie þas tis mû sø ty ri me bu vo at si tik ti nis pamir ði mas, o sàmo nin gai vais tø ne var to jo dël pras tos ar ba ge res nës sa vijau tos tik la bai ma þa da lis at sa kiu siø jø. Pa na ðius re zul ta tus pa skel bë ir ki ti au to riai, ver ti nae imu no mo du liuo jan èio gydy mo var to ji mo draus min gu mà tarp ser gan èiø jø IS -pagrin di në ne draus min go vais tø var to ji mo prie þas tis taip pat bu vo at si tik ti nis pamir ði mas, o ki tos prie þas tys uþ ëmë kur kas ma þes nae da lá [19][20][21].…”

“…Nu sta të me, kad ap klau sos me tu res pon den tai pa ti kimai daþ niau pa mirð da vo ið ger ti vais tus tab le të mis ar ba kap su lë mis, nei su si leis ti po oda ar ba á rau me nis. Pa sau lio stu di jø, ver ti nu siø lei dþia mø ar ba pe ro ra li niø vais tø varto ji mo draus min gu mà, re zul ta tai yra prieð ta rin gi [21][22][23][24][25]. Jei gu vie ni ty ri mai sta tis tið kai pa ti ki mo skir tu mo tarp draus min gu mo, var to jant vais tus tab le të mis ar ba kap su lëmis ar ba lei dþian tis in jek ci jas po oda ar á rau me nis, ne randa [21,22], tai ki ti ty ri mai áro do, kad vais tø var to ji mo forma tu ri áta kos LEM vais tø draus min gu mui [26,27].…”

“…Pa sau lio stu di jø, ver ti nu siø lei dþia mø ar ba pe ro ra li niø vais tø varto ji mo draus min gu mà, re zul ta tai yra prieð ta rin gi [21][22][23][24][25]. Jei gu vie ni ty ri mai sta tis tið kai pa ti ki mo skir tu mo tarp draus min gu mo, var to jant vais tus tab le të mis ar ba kap su lëmis ar ba lei dþian tis in jek ci jas po oda ar á rau me nis, ne randa [21,22], tai ki ti ty ri mai áro do, kad vais tø var to ji mo forma tu ri áta kos LEM vais tø draus min gu mui [26,27]. Taèiau, anot dau ge lio ty ri mø, svar biau si fak to riai, tu rin tys áta kos draus min gam LEM vais tø var to ji mui, yra am þius (18-34 m.), vy rið ka ly tis ir dep re si jos ne bu vi mas [22][23][24][25].…”

<p>BetaEval Global: Prospective, Multinational, Observational Cohort Study of Patients Using BETACONNECT^®</p>

“…2,[11][12][13][14] It has been reported that injectable DMTs for regular selfadministration have slightly higher adherence (68%) than orally administered DMTs (63%). 15 The use of autoinjectors to administer injectable DMTs has been associated with improved adherence by, among other factors, reducing the rate at which injection site reactions occur. 11,16 BETACONNECT ® is a fully electronic autoinjector for interferon beta-1b (Betaferon ® /Betaseron ® ; Bayer AG; Berlin, Germany) that incorporates a number of features to facilitate the injection process, including a four-phase injection technology and individual control of injection speed, depth, dwell time, and needle retraction rate.…”

Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care

“…Patient adherence is an important factor in MS management [4–6], but can be compromised by poor satisfaction with therapy, perceived lack of efficacy, and the occurrence of side effects and tolerability issues [7, 8]. Good patient–healthcare professional (HCP) communication plays a key role in improving treatment satisfaction and treatment adherence [7, 9, 10].…”